- Antiparasitic treatment
- Symptomatic treatment
Chagas Disease Management Market was valued at USD 5.72 Mn in 2021 and is expected to witness a CAGR of 7.6% over the forecast period 2022-2028. Chagas disease or American trypanosomiasis is a tropical parasitic disease caused by Trypanosoma cruzi. Chagas disease is transmitted by kissing bugs or triatomine bugs. Chagas disease can also transmit through blood transfusions, mother to foetus during pregnancy, and sometimes it causes through organ transplantation. The symptoms of the Chagas disease in early stage include swollen lymph nodes, fever, headache, and local swelling at the site of the bite. The chronic symptoms will appear after 8-12 weeks that may include expansion of ventricles leads to the heart failure, oesophagus or colon may cause death. The diagnosis of Chagas disease is complicated, require laboratory analysis of blood samples for the detection of antibodies against the Trypanosome cruzi. The Chagas disease is majorly present in the Latin America and spreading to North America and Europe region. Increase in the Chagas disease population in Latin America region, rise in the prevalence of Chagas disease due to unhygienic conditions might fuel the growth of Chagas disease management market over the forecast period. In addition, increase in the research and development of new products are one of the main factors that drive the growth of chagas disease management market. However, lack of awareness regarding the chagas disease treatment, a limited number of approved products in the current market, and supply chain issues with chagas disease drugs will hamper the growth of the chagas disease management market over the forecast period. In March 2017, Daiichi Sankyo Company Limited and Drugs for Neglected Diseases initiative (DNDi) are collaborated to form a joint research with regard to a new research program, the hit-to-lead project to develop the drugs for Chagas disease and leishmaniasis
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Benznidazole is a vital antiparasitic medication used to treat Chagas disease. The Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT) approved benznidazole, a medication developed by Laboratorio Elea Phoenix SA, for paediatric use in the treatment of Chagas disease in April 2018. Argentina now has the highest number of people infected with the Chagas disease. According to data given by Mundo Sano (an Argentine non-governmental organisation), over 7,300,000 people in Argentina were exposed to Chagas disease in 2017, with about 1,600,000 becoming infected. As a result, new drug approvals are projected to drive market growth in the near future.The approval of medications to treat Chagas disease is projected to drive the Chagas Disease Management Market's growth in the near future. The campaign aims to raise public awareness about Chagas disease, which is still widespread in Latin American countries and affects around 6 million people worldwide. The World Health Organization (WHO) initiated a programme in 2007 to raise Chagas disease treatment rates and eradicate the disease. Bayer HealthCare, which makes the drug nifurtimox, which is used to treat Chagas disease, contributed to this WHO initiative. From 2012 through 2017, Bayer is expected to distribute 5 million tablets free of charge, according to the deal. In the foreseeable future, such initiatives are projected to boost market expansion.
The chagas disease management market is projected to expand at a CAGR of 7.6% during the forecast period.
AstraZeneca, Bayer AG, Daiichi Sankyo Company Ltd, Eisai Co Ltd, GlaxoSmithKline Plc., Grupo Praxis Pharmaceutical SA, KaloBios Pharmaceuticals, Kancera AB
[urltag url='request-table-of-content']